Discover the new Chem-Impex: Where innovation starts with a bond.

Catalog Number:
37832
CAS Number:
1110813-31-4
Dacomitinib
Purity:
≥ 98% (HPLC)
Synonym(s):
PF 00299804, (E)-N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxyquinazolin-6-yl]-4-(piperidin-1-yl)but-2-enamide
Documents
$201.60 /50MG
Pack Size Availability Price
Request Bulk Quote
Product Information

Dacomitinib is a potent and selective irreversible inhibitor of the epidermal growth factor receptor (EGFR), primarily utilized in the treatment of non-small cell lung cancer (NSCLC). This compound is particularly effective against tumors with specific EGFR mutations, making it a valuable option for targeted therapy. Dacomitinib's unique mechanism of action allows for sustained inhibition of EGFR signaling pathways, which can lead to improved clinical outcomes in patients who have not responded to traditional therapies.

In addition to its application in oncology, Dacomitinib is being explored in combination therapies to enhance its efficacy and overcome resistance mechanisms in cancer treatment. Its favorable pharmacokinetic profile and ability to penetrate the blood-brain barrier also position it as a promising candidate for addressing central nervous system metastases. Researchers and healthcare professionals can leverage Dacomitinib's targeted action to optimize treatment regimens and improve patient quality of life.

Synonyms
PF 00299804, (E)-N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxyquinazolin-6-yl]-4-(piperidin-1-yl)but-2-enamide
CAS Number
1110813-31-4
Purity
≥ 98% (HPLC)
Molecular Formula
C24H25ClFN5O2
Molecular Weight
469.95
MDL Number
MFCD19443734
PubChem ID
57519532
Appearance
White to light yellow powder to crystal
Conditions
Store at < 0 °C
General Information
Synonyms
PF 00299804, (E)-N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxyquinazolin-6-yl]-4-(piperidin-1-yl)but-2-enamide
CAS Number
1110813-31-4
Purity
≥ 98% (HPLC)
Molecular Formula
C24H25ClFN5O2
Molecular Weight
469.95
MDL Number
MFCD19443734
PubChem ID
57519532
Appearance
White to light yellow powder to crystal
Conditions
Store at < 0 °C
Properties
Additional property information coming soon!
-
Safety and Regulations
Hazmat
No
Antibiotic
No
DEA-regulated
No
Warnings
-
Applications

Dacomitinib is widely utilized in research focused on:

  • Targeted Cancer Therapy: This compound is primarily used in the treatment of non-small cell lung cancer (NSCLC). By inhibiting specific pathways, it helps to block tumor growth and spread, offering a more effective treatment option compared to traditional chemotherapy.
  • Clinical Trials: Dacomitinib is frequently involved in clinical trials aimed at evaluating its efficacy and safety in various cancer types. Researchers benefit from its targeted action, which allows for more precise patient selection and potentially better outcomes.
  • Personalized Medicine: The use of Dacomitinib supports the growing field of personalized medicine, where treatments are tailored based on genetic markers. This approach enhances treatment effectiveness and minimizes side effects for patients with specific mutations.
  • Combination Therapies: It is often studied in combination with other therapeutic agents to improve treatment regimens. This strategy can lead to synergistic effects, increasing the overall effectiveness against resistant cancer types.
  • Research on Resistance Mechanisms: Dacomitinib is valuable in research aimed at understanding resistance mechanisms in cancer therapies. Insights gained can guide the development of next-generation inhibitors and improve treatment strategies.

Citations